- Home
- JLL vs ICLR Comparison
JLL vs ICLR Comparison
Compare JLL & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JLL
- ICLR
- Stock Information
- Founded
- JLL 1997
- ICLR 1990
- Country
- JLL United States
- ICLR Ireland
- Employees
- JLL N/A
- ICLR N/A
- Industry
- JLL Real Estate
- ICLR Biotechnology: Commercial Physical & Biological Resarch
- Sector
- JLL Finance
- ICLR Health Care
- Exchange
- JLL Nasdaq
- ICLR Nasdaq
- Market Cap
- JLL 12.1B
- ICLR 11.6B
- IPO Year
- JLL 1997
- ICLR 1998
- Fundamental
- Price
- JLL $255.83
- ICLR $149.52
- Analyst Decision
- JLL Strong Buy
- ICLR Buy
- Analyst Count
- JLL 7
- ICLR 12
- Target Price
- JLL $310.00
- ICLR $187.82
- AVG Volume (30 Days)
- JLL 490.0K
- ICLR 1.1M
- Earning Date
- JLL 08-06-2025
- ICLR 07-23-2025
- Dividend Yield
- JLL N/A
- ICLR N/A
- EPS Growth
- JLL 78.40
- ICLR 11.53
- EPS
- JLL 11.07
- ICLR 9.19
- Revenue
- JLL $24,054,800,000.00
- ICLR $8,192,621,999.00
- Revenue This Year
- JLL $10.02
- ICLR N/A
- Revenue Next Year
- JLL $8.25
- ICLR $1.69
- P/E Ratio
- JLL $23.22
- ICLR $16.38
- Revenue Growth
- JLL 13.63
- ICLR N/A
- 52 Week Low
- JLL $194.36
- ICLR $125.10
- 52 Week High
- JLL $288.50
- ICLR $347.72
- Technical
- Relative Strength Index (RSI)
- JLL 59.72
- ICLR 55.90
- Support Level
- JLL $251.91
- ICLR $148.03
- Resistance Level
- JLL $261.32
- ICLR $155.90
- Average True Range (ATR)
- JLL 5.41
- ICLR 4.81
- MACD
- JLL -0.30
- ICLR 0.05
- Stochastic Oscillator
- JLL 66.09
- ICLR 50.96
About JLL Jones Lang LaSalle Incorporated
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $74 billion for clients across diverse public and private real estate strategies.
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.